Warren Center For Neuroscience Drug Discovery

Craig Lindsley, the William K. Warren, Jr. Professor of Medicine and director of Vanderbilt University’s  Warren Center for Neuroscience Drug Discovery, and Jeffrey Conn, founding director of the WCNDD and professor emeritus of pharmacology, have contributed seminal work… Read More

Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Down syndrome is a condition in which a person’s having… Read More

A drug aimed at improving the lives of patients living with Parkinson’s disease will go to the next phase of clinical trials, thanks to a $13.5 million investment raised by Nashville’s Appello Pharmaceuticals. The clinical-stage pharmaceutical company that focuses on nervous system disorders announced Tuesday that its lead drug,… Read More

Cannabis is well-known for having an effect on eating behaviors. However, how the natural cannabinoid molecules found in the body regulate feeding and eating is not well researched. Masoud Ghamari-Langroudi, research assistant professor of molecular physiology and biophysics, research assistant professor of pharmacology and faculty affiliate… Read More

Vanderbilt University has signed an exclusive, worldwide license and a research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.   The licensed program centers around the M4 muscarinic receptor positive allosteric modulator—including… Read More

Stressful experiences can lead to adaptive or detrimental behaviors. Understanding how stress can affect our brains can help understand basic brain function and is also essential to discerning causes and treatments for some diseases. A group of researchers led by Jeffrey Conn, professor of pharmacology at… Read More

Vanderbilt has extended its longest ongoing drug discovery agreement with Osaka, Japan-based Ono Pharmaceutical Co., Ltd., a research and development-oriented pharmaceutical company that is committed to creating innovative medicines in specific areas, through November 2023. The initial agreement was signed in November… Read More